Diversify Wealth Management LLC Has $2.66 Million Stake in Medpace Holdings, Inc. $MEDP

Diversify Wealth Management LLC lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,016 shares of the company’s stock after selling 1,413 shares during the period. Diversify Wealth Management LLC’s holdings in Medpace were worth $2,656,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Allied Private Wealth LLC bought a new stake in shares of Medpace in the second quarter valued at about $31,000. Basecamp Wealth Advisors LLC grew its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after acquiring an additional 45 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Medpace in the third quarter valued at about $35,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and increased their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. BMO Capital Markets lifted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $584.18.

Medpace Trading Down 2.5%

Medpace stock opened at $581.95 on Friday. The company has a market capitalization of $16.24 billion, a PE ratio of 34.11, a P/E/G ratio of 2.66 and a beta of 1.15. The stock has a 50-day moving average price of $533.75 and a two-hundred day moving average price of $491.74. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business earned $3.10 EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of Medpace stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the transaction, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 55,371 shares of company stock worth $30,878,030 over the last ninety days. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.